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The  CRISPR-Cas9  system  has  become  the  most  popular  and  efﬁcient  method  for  genome  engineering  in
mammalian  cells.  The  Streptococcus  pyogenes  Cas9  nuclease  can  function  with  two  types  of guide  RNAs:
the  native  dual  crRNA  and  tracrRNA  (crRNA:tracrRNA)  or a chimeric  single  guide  RNA  (sgRNA).  Although
sgRNAs  expressed  from  a DNA  vector  are predominant  in the  literature,  guide RNAs  can  be  rapidly  gener-
ated  by  chemical  synthesis  and  provide  equivalent  functionality  in  gene  editing  experiments.  This  review
highlights  the  attributes  and  advantages  of  chemically  synthesized  guide  RNAs  including  the  incorpo-NA synthesis
ene editing
ynthetic crRNA
ynthetic tracrRNA
ual RNA
ration  of  chemical  modiﬁcations  to enhance  gene  editing  efﬁciencies  in  certain  applications.  The use  of
synthetic  guide  RNAs  is  also  uniquely  suited  to genome-scale  high  throughput  arrayed  screening,  particu-
larly when  using  complex  phenotypic  assays  for functional  genomics  studies.  Finally,  the  use  of synthetic
guide  RNAs  along  with  DNA-free  sources  of  Cas9  (mRNA  or protein)  allows  for  transient  CRISPR-Cas9
presence  in  the cell,  thereby  resulting  in  a decreased  probability  of off-target  events.
©  2016  The  Author(s).  Published  by Elsevier  B.V.  This  is  an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction and the trans-activating crRNA (tracrRNA), to direct sequence-
speciﬁc cleavage of foreign DNA. This bacterial acquired immuneThe clustered regularly interspaced palindromic repeats
CRISPR)-associated protein 9 (Cas9) system is an RNA-guided
efense mechanism in bacteria and archaea. In these organisms, the
as9 nuclease associates with two RNAs, the CRISPR RNA (crRNA)
∗ Corresponding author.
E-mail address: anja.smith@ge.com (A.v.B. Smith).
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.0/).system has been shown to be effective for gene editing in mam-
malian cells, and is now routinely used as an effective genome
engineering tool in multiple organisms (Jinek et al., 2012; Mali
et al., 2013; Cong et al., 2013; Jinek et al., 2013). The most com-
monly used system in mammalian cell applications is derived
from the Streptococcus pyogenes Type II CRISPR-Cas9 system and
consists of the Cas9 protein as the nuclease that cleaves double-
strand DNA when guided by the crRNA and tracrRNA (dual RNA)
e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. The S. pyogenes CRISPR-Cas9 can be programmed by two separate RNAs or a long single guide RNA for efﬁcient gene editing. (a) The native CRISPR-Cas9 system contains
three  components: the Cas9 protein (blue circles), the crRNA (green), and the tracrRNA (blue) which form a complex that binds to the target genomic DNA (gDNA, black)
upstream of a protospacer-adjacent motif (PAM, red) and results in site-speciﬁc cleavage. (b) The sgRNA combines the crRNA and tracrRNA into one chimeric transcript for
utility  in generation of expression vectors and in vitro transcribed constructs. (c) Dual synthetic crRNA:tracrRNAs have similar gene editing efﬁciencies to synthetic sgRNAs
or  in vitro transcribed sgRNAs. HeLa and U2OS cells were plated at 10,000 cells/well one day prior to transfection. Cells were transfected with either Edit-RTM crRNA:tracrRNA
(25  nM)  or synthetic 99-mer sgRNA (25 nM)  or in vitro transcribed 99-mer sgRNA (25 nM) and Edit-R Cas9 Nuclease protein (25 nM)  using DharmaFECT Duo transfection
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 (T7EI; NEB) was  performed 72 h post-transfection to estimate gene editing efﬁcie
egend, the reader is referred to the web version of this article.).
Fig. 1a). Upon site-speciﬁc double-strand DNA cleavage, mam-
alian cells repair the break through multiple DNA double-strand
reak (DSB) repair pathways; the predominant pathways are
on-homologous end-joining (NHEJ) which results in imprecise
nsertions and deletions (indels), and homology-directed repair
HDR) which results in precise genome editing when a donor tem-
late is available.
In order to facilitate expression of the RNAs, Jinek et al. demon-
trated that the crRNA and tracrRNA could be expressed as a single
NA molecule resulting in effective gene editing in mammalian
ells (Jinek et al., 2012). This chimeric single guide RNA (sgRNA)
ombines the crRNA and the tracrRNA into a continuous sequence
ttached by a loop (Fig. 1b) and has comparable functionality to the
ative dual RNA system (Cas9:crRNA:tracrRNA) (Jinek et al., 2012).
he use of the chimeric sgRNA facilitates the cloning and expression
f the two small RNAs as a single transcript for expression vectors,
onstructs for in vitro transcription, and viral vectors for pooled
ibrary screening. Given the ease of cloning and expressing a single
uide RNA molecule rather than the crRNA and the tracrRNA sepa-
ately, it is not surprising that the majority of publications thus far
ave utilized the CRISPR-Cas9 system with an expressed chimeric
gRNA. Nonetheless, our data ((Anderson et al., 2015) and Fig. 1c)
s well as data from recent publications (Aida et al., 2015; Kotani
t al., 2015; Sivan et al., 2015 Sivan et al., 2015) have conﬁrmed
he original Jinek et al. ﬁndings, demonstrating that the native,
ual RNA complex functions similarly to the sgRNA. For the pur-
oses of this review, we will refer to the RNA component of the
RISPR-Cas9 system as the guide RNA (gRNA), which may  consistcon, part of GE Healthcare). A DNA mismatch detection assay using T7 Endonuclease
ercentage under gel). (For interpretation of the references to colour in this ﬁgure
of either the chimeric single guide RNA (sgRNA) or the dual RNAs
(crRNA:tracrRNA).
2. Chemical synthesis of the guide RNA
The RNA components of the CRISPR-Cas9 system can be gen-
erated enzymatically or through chemical synthesis. Enzymatic
synthesis of the gRNA by in vitro transcription utilizes T7, T3, or SP6
RNA polymerase in the presence of ribonucleoside triphosphates
and a DNA template, and is a cost-effective method for generat-
ing unmodiﬁed RNAs of different lengths, including generation of
sgRNAs (Cho et al., 2013). However, the method requires sequenc-
ing of the DNA template for accuracy, removal of unincorporated
triphosphates, and puriﬁcation of protein and DNA components
from the transcribed RNA. Additionally, this method can result in
errors toward the 5′ end of the molecule (Helm et al., 1999).
Chemical generation of gRNAs utilizes solid-phase synthesis
with nucleoside phosphoramidite building blocks to construct the
gRNA. This method has the ﬂexibility to quickly and accurately
generate different sequences and lengths of RNA without the
need for multiple cloning and sequencing steps. Several differ-
ent types of solid-phase RNA synthesis chemistries are available
including 2′-silyl (2′-TBDMS, 2′-TOM), 2′-O-thionocarbamate (TC)
(Dellinger et al., 2011) and 2′-bis(acetoxyethoxy)-methyl ether
(2′-ACE) (Scaringe, 2000; Scaringe, 2001; Scaringe et al., 1998).
Chemical synthesis of gRNAs has been used to successfully gener-
ate gRNA sequences for S. pyogenes Cas9 systems (Anderson et al.,
2015) and can be used to generate RNAs for programming of alter-
76 M.L. Kelley et al. / Journal of Biotechnology 233 (2016) 74–83
Fig. 2. Synthetic gRNAs can be applied to a variety of CRISPR-Cas9 experimental approaches. (a) Dual RNA can be co-delivered with Cas9 mRNA, Cas9 protein, or a Cas9
expression plasmid, or delivered into a stable Cas9-expressing cell line. Delivery can be achieved using a variety of methods resulting in efﬁcient gene editing. (b) U2OS
cells  were plated at 10,000 cells/well one day prior to transfection. Cells were transfected with either Edit-R Cas9 Nuclease plasmid (200 ng), Edit-R Cas9 Nuclease mRNA
(200  ng) or Cas9 nuclease protein (25 nM)  and crRNA:tracrRNA (25 nM)  targeting PPIB using DharmaFECT Duo transfection reagent (0.4 L/well) in biological triplicates.
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tc)  U2OS-CAG-Cas9 stable cells were plated at 10,000 cells/well one day prior to 
harmaFECT 1 transfection reagent (0.2 L/well) in biological triplicates. A DNA mis
diting  efﬁciency (percentage under gel).
ate Cas9 nucleases, species, or CRISPR-Cas systems (Cong et al.,
013; Kleinstiver et al., 2015a; Kleinstiver et al., 2015b; Ran et al.,
015; Kleinstiver et al., 2016). It is important to note that with
raditional chemistries, such as TBDMS or 2′-TOM (Pitsch et al.,
001; Sproat, 2005), it can be challenging to accurately and efﬁ-
iently synthesize RNA greater than ∼70 bases. For S. pyogenes,
he crRNA, tracrRNA and sgRNA are approximately 40, 70 and
00 nucleotides in length, respectively (Jinek et al., 2012), which
ould make synthesis of the tracrRNA or an sgRNA challenging for
ost chemistries. Using 2′-ACE or TC chemistries (Scaringe, 2001;
ellinger et al., 2011), long RNA (up to 150 nucleotides) can be
outinely synthesized with faster coupling rates, higher yields and
reater purity than any other RNA chemistries, thus making these
ynthesis methods ideal for tracrRNA and sgRNA syntheses.
The relatively shorter length of the S. pyogenes Cas9 nuclease
rRNA (∼40 nucleotides) allows for high throughput chemical syn-
hesis and rapid generation of crRNAs in large numbers. Using this
pproach, arrayed genome-scale collections of gene engineering
eagents can be easily produced and used for large-scale func-
ional genomics studies as discussed in more detail below. The
70 nucleotide tracrRNA can be synthesized and puriﬁed in bulk
or use with the target-speciﬁc crRNA. Synthetic crRNA:tracrRNAs
s compatible with a variety of delivery methods including lipid
ransfection, electroporation, and microinjection and are there-
ore suitable for a wide variety of gene editing applications when
ombined with a source of Cas9 (Fig. 2a). As shown in Fig. 2b,
he synthetic crRNA:tracrRNA reagents can be co-delivered with
 plasmid expressing Cas9, Cas9 mRNA, or Cas9 protein, or can be
elivered on their own into cells that are stably expressing Cas9
Fig. 2c). In all cases, genome editing is achieved, as indicated by
he formation of indels at the site of the CRISPR-Cas9-mediated
ouble-strand DNA break.
If a synthetic chimeric single guide RNA (sgRNA) is desired,
sing RNA chemistries such as 2′-ACE or 2′-TC that result in accu-
ate synthesis of such long RNAs (∼100 nucleotides) is essential.
he synthesis of long RNAs, even with ideal synthesis approaches,
till requires longer synthesis times and results in lower yields
ompared to shorter RNA syntheses and typically requires addi-
ional puriﬁcation. Therefore, the synthesis of sgRNAs will generallyection. Cells were transfected with crRNA:tracrRNA (25 nM) targeting PPIB using
 detection assay using T7EI was performed 72 h post-transfection to estimate gene
be achieved with a lower throughput compared to the dual RNA
approach.
3. Chemical modiﬁcations of the synthetic guide RNA
Chemical synthesis is the only method that allows for the incor-
poration of site-speciﬁc chemical modiﬁcations in gRNA. The type
and position of chemical modiﬁcations can be hypothesized based
on the unique features of the CRISPR-Cas9 system as well as the
lessons learned from existing RNA-based gene modulation tech-
nologies (Barrangou et al., 2015). Chemical modiﬁcations of RNAs
for other technologies have been used for improving editing efﬁ-
ciency, speciﬁcity, in vivo stability, cellular delivery and evading
the innate immune system (Judge et al., 2006; Cekaite et al., 2007;
Kariko et al., 2005).
A large body of work studying synthetic oligonucleotides has
elucidated rules for chemical modiﬁcations that may  be appli-
cable to the gRNA of the CRISPR-Cas9 system (Gori et al., 2015;
Juliano et al., 2008). Chemical modiﬁcations can be applied to the
oligonucleotide’s phosphate backbone, sugar, and/or base (Fig. 3).
Backbone modiﬁcations such as phosphorothioates modify the
charge on the phosphate backbone and aid in the delivery and
nuclease resistance of the oligonucleotide (Eckstein, 2014); modiﬁ-
cations of the sugar, such as 2′-O-methyl (2′-OMe), 2′-F, and locked
nucleic acid (LNA), enhance base pairing as well as nuclease resis-
tance (Allerson et al., 2005). Chemically modiﬁed bases such as
2-thiouridine or N6-methyladenosine, among others, can allow for
either stronger or weaker base pairing (Bramsen and Kjems, 2012;
Sharma et al., 2014). Additionally, RNA is amenable to both 5′ and
3′ end conjugations with a variety of functional moieties including
ﬂuorescent dyes, polyethylene glycol, or proteins. A wide variety
of potential modiﬁcations can be applied to a chemically synthe-
sized RNA molecule, yet any type of chemical modiﬁcation alters
the fundamental oligonucleotide structure and can therefore affect
any step in the CRISPR-Cas9 gene editing mechanism. For example,
modifying an oligonucleotide with a 2′-OMe to improve nuclease
resistance will also change the binding energy of Watson-Crick base
pairing. Furthermore, a 2′-OMe modiﬁcation can affect how the
oligonucleotide interacts with a transfection reagent, proteins or
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Fig. 3. Synthetic gRNAs permit chemical modiﬁcations. Chemical modiﬁcations can
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Fig. 4. Chemical modiﬁcations enhance the nuclease stability of synthetic gRNAs for
delivery by electroporation. (a) Effective gene editing requires sequential electropo-
ration when using Cas9 mRNA and unmodiﬁed synthetic crRNA:tracrRNA. Effective
gene editing with co-delivery of Cas9 mRNA and synthetic crRNA:tracrRNA requires
the  addition of modiﬁcations to the crRNA and tracrRNA molecules. crRNA and tracr-
RNA with three MS modiﬁcations on both the 5′ and 3′ ends (3xMS) provide nuclease
resistance and allow for co-delivery by electroporation for gene editing. Electropora-
tion of Cas9 mRNA (5 g) and synthetic crRNA:tracrRNA (5.36 M) into K562 cells
(2 million) was  performed using a NucleofectorTM 2b (Lonza). Sequential electro-
poration was performed with Cas9 mRNA ﬁrst and followed by electroporation of
unmodiﬁed synthetic crRNA:tracrRNA 6 h later. A DNA mismatch detection assay
using T7EI was performed 72 h post-transfection to estimate gene editing efﬁciency
(percentage under gel). (b) Modiﬁcations are not necessary for lipid transfection
of  synthetic crRNA:tracrRNA with Cas9 mRNA as similar levels of gene editing
were calculated for 3xMS modiﬁed and unmodiﬁed dual RNA. U2OS cells were
plated at 10,000 cells/well one day prior to transfection. Cells were transfected with
Cas9 Nuclease mRNA (200 ng) and crRNA:tracrRNA (25 nM)  using DharmaFECT Duo
transfection reagent (0.4 L/well) in biological triplicates. A DNA mismatch detec-e  applied to the RNA backbone, base, and/or sugar. Covalent conjugations on 5′ and
′ ends are also possible.
ny other molecule in the cell. Therefore, empirical testing to deter-
ine the advantages and potential disadvantages of any chemical
odiﬁcation on functionality of the gRNA is essential.
A few examples applying chemical modiﬁcation strategies to
ynthetic sgRNAs for CRISPR-Cas9-based techniques have been
eported to date (Hendel et al., 2015; Rahdar et al., 2015; Deng
t al., 2015). A synthetic RNA approach was used to optimize
rRNA length, and chemical modiﬁcations were applied to both
he phosphate backbone and sugar to improve resistance to nucle-
se digestion, hybridization to tracrRNA and pharmacokinetics
Rahdar et al., 2015). Modiﬁcations including phosphorothioates,
′-OMe, 2′-F, and 2′-constrained ethyl (2′-cEt) were applied to
egions of the crRNA that recognize their DNA targets or to the
racrRNA anti-repeat region and were found to increase the efﬁ-
iency of gene disruption compared to unmodiﬁed crRNA. Hendel
t al. tested sgRNAs with both backbone and sugar modiﬁcations
hat confer nuclease stability and can reduce immunostimulatory
ffects (Hendel et al., 2015). Upon co-electroporation or sequential
lectroporation of Cas9 mRNA and modiﬁed synthetic sgRNAs in
uman primary immune cells, sgRNAs containing 2′-OMe, 2′-OMe
′-phosphorothioate (MS), or 2′-OMe 3′-thioPACE (MSP) modiﬁ-
ations resulted in ten times higher editing frequencies than the
nmodiﬁed sgRNA. Modiﬁcations to the sgRNA also improved gene
diting efﬁciencies (approximately three fold) when delivering
he modiﬁed sgRNA complexed with the Cas9 protein as RNPs;
hese improvements in editing efﬁciencies are primarily due to
nhanced nuclease stability. While chemical modiﬁcations of syn-
hetic sgRNAs (MS  and MSP  modiﬁcations) improved the nuclease
tability and editing efﬁciency in human primary T cells and CD34+
ematopoietic stem and progenitor cells, they did not provide any
onsistent ability to reduce off-target effects, as variable sequence-
peciﬁc effects were observed (Hendel et al., 2015). Chemically
odiﬁed crRNAs are likely to exhibit editing-independent effects
hat are based on the mechanisms of oligonucleotide-based mod-
lation tools such as antisense, siRNA, and aptamers. For example,
e observed that modiﬁed crRNAs with >50% 2′-F modiﬁcations
n the DNA binding region sequence-speciﬁcally reduced gene
xpression without the presence of Cas9 protein, suggesting an
ntisense-type mechanism (data not shown). Chemically modiﬁed
rRNAs may  also exhibit effects such as cellular toxicity and innate
mmune response due to the structure of the modiﬁed oligonu-tion assay using T7EI was  performed 72 h post-transfection to estimate gene editing
efﬁciency (percentage under gel).
cleotide. Indeed, similar to observations in siRNA and antisense
molecules (Hough et al., 2003), we observed toxicity of crRNAs with
phosphorothioate chemical modiﬁcations in certain structural con-
texts (data not shown). While researchers in the ﬁeld are using
chemical modiﬁcations to reduce off-target effects and the innate
immune response, studies to examine the editing-independent
effects of chemically modiﬁed gRNAs are only now underway.
Similar to the observations using modiﬁed sgRNAs, we have
found that chemical modiﬁcations can enhance editing efﬁciency
by improving nuclease stability of the synthetic dual RNA system
when utilizing certain delivery methods. For example, if unmod-
iﬁed synthetic crRNA:tracrRNAs are co-electroporated with Cas9
mRNA, editing is not detected (Fig. 4a). However, if Cas9 mRNA is
electroporated ﬁrst and unmodiﬁed crRNA:tracrRNA is electropo-
rated 6 h later (sequential electroporation), efﬁcient gene editing
is observed. When both crRNA and tracrRNA are chemically modi-
ﬁed for nuclease stability with three 2′-OMe 3′-phosphorothioates
(3xMS) on the 5′ and 3′ ends, efﬁcient gene editing is achieved
when these modiﬁed crRNA:tracrRNAs are co-electroporated with
Cas9 mRNA, similar to what was demonstrated for sgRNAs (Hendel
et al., 2015). MS  modiﬁcations do not improve editing in sequential
electroporation, suggesting that the modiﬁcations are not inher-
ently improving the CRISPR-Cas9 gene editing mechanism, but are
instead enhancing nuclease stability of the RNAs so they remain
intact and are able to be loaded into Cas9 once the Cas9 mRNA
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s translated into protein. Chemical modiﬁcations that enhance
uclease stability are not required for lipid-mediated delivery of
as9 mRNA and crRNA:tracrRNA and do not enhance the overall
evel of indel formation (Figs. 1 c, 2 b, and 4 b). This result is likely
ue to protection of the unmodiﬁed RNAs in the lipid complex dur-
ng delivery, and rapid complexing of the Cas9 protein and the RNA
esulting in DSBs (Zuris et al., 2015; Kim et al., 2014).
In terms of therapeutic applications, the CRISPR-Cas9 system
ill likely face similar obstacles as small interfering RNA (siRNA)
nd antisense therapeutics due to the inherent features of the RNA:
oor intracellular delivery, limited in vivo stability, unpredictable
mmune responses, and unwanted off-targeting effects. However,
he CRISPR-Cas9 system has unique physical and mechanistic prop-
rties compared to RNAi and antisense technologies. The crystal
tructures of the active Cas9:gRNA ribonucleoprotein (RNP) com-
lex show that the gRNA is bound within the large Cas9 protein and
uch of the RNA is not exposed to solvent (Nishimasu et al., 2014;
inek et al., 2014; Jiang et al., 2016). These data provide the ability
o make informed choices regarding potential positions on the RNA
here chemical modiﬁcations to improve therapeutic properties,
uch as nuclease resistance or speciﬁcity, are feasible. Furthermore,
he gene editing mechanism of CRISPR-Cas9 results in a perma-
ent change in the genome; therefore, persistent application of
he CRISPR-Cas9 molecules is not necessary and stability of the
NA may  not be a requirement for therapeutics. Indeed, it may
e preferable to have CRISPR-Cas9 components persist just long
nough to result in the genome edit. Such transient delivery can be
chieved by delivering the relatively cationic Cas9 protein and the
nionic gRNA as an RNP complex in cells or in vivo (Zuris et al., 2015)
sing either lipid-mediated delivery or electroporation (Schumann
t al., 2015). Evasion of the innate immune system may  be less of
 challenge using this approach, as exposure to immunogenic RNA
s limited.
. CRISPR-Cas9 speciﬁcity
Whether using synthetic gRNAs or expressed sgRNAs for
RISPR-Cas9 experimentation, the desired outcome is to exclu-
ively target the intended genomic location and avoid any editing
vents in other regions of the genome. Several early studies demon-
trated that the nuclease activity of Cas9 can be triggered at
arget sites with imperfect complementarity between the target
NA and the gRNA sequences; these regions of imperfect comple-
entarity included mismatches (Fu et al., 2013; Hsu et al., 2013;
attanayak et al., 2013) and insertions or deletions between the
arget DNA and the gRNAs (Lin et al., 2014). The tolerance of mis-
atches and gaps/bulges (ﬂaws) between any given gRNA and
arget DNA is sequence-dependent and inﬂuenced by the position,
umber and distribution of these ﬂaws throughout the ∼20 nt tar-
et sequence. Multiple studies, including ours, have shown that
ingle mismatches are generally well-tolerated at the 5′ end of the
RNA target region, but are less tolerated at the PAM proximal end
Anderson et al., 2015; Fu et al., 2013; Hsu et al., 2013). This result is
onsistent with a model in which the “seed” region complementar-
ty drives selectivity (Jinek et al., 2012; Jiang et al., 2013); however,
his is sequence dependent and the size of this seed region can
ary from 7 to 12 nucleotides. Two adjacent mismatches are not
ell tolerated compared to single mismatches, but can still result
n cleavage for some sequences, while three or more adjacent mis-
atches generally decrease or eliminate activity. In addition, Lin
t al. showed that Cas9 can have off-target cleavage when DNA
equences have an extra base (DNA bulge) or a missing base (gRNA
ulge) at various locations compared to the corresponding gRNA
trand (Lin et al., 2014). The correlation between cleavage activity
nd the position of the DNA bulge or gRNA bulge relative to the PAMhnology 233 (2016) 74–83
appeared to be GC content and sequence dependent. While both
RNA and DNA bulges can lead to off-target editing, it was found that
gRNAs bulges are better tolerated, therefore maintaining formation
of DSBs, than DNA bulges of similar size.
While these early references on CRISPR-Cas9 speciﬁcity demon-
strate off-target cleavage with varying frequencies at genomic sites
based on computational predictions (Fu et al., 2013; Hsu et al.,
2013; Pattanayak et al., 2013), the extent of off-target effects on
the genome as a whole remains unclear. Some studies suggest that
CRISPR-Cas9 has substantial off-targeting activity (Fu et al., 2013;
Cradick et al., 2013), while other studies, including whole genome
sequencing of human pluripotent stem cell (PSC) and induced PSC
clones (Veres et al., 2014; Smith et al., 2014) detected very few to
no off-target mutations. The need to further characterize off-target
effects on a genome-wide scale in an unbiased manner has resulted
in a variety of whole genome mutation analysis techniques; some
newly developed techniques include GUIDE-seq (Tsai et al., 2015),
Digenome-Seq (Kim et al., 2015), BLESS (Crosetto et al., 2013),
HTGTS (Frock et al., 2015) and IDLV (Wang et al., 2015). Neverthe-
less, even with these new whole genome methods for detection
of off-targets, there still are contradictory conclusions as to the
prevalence of off-target effects, from low (Kim et al., 2015) to high
levels of off-targeting (Tsai et al., 2015); these discrepancies can be
attributed to differences in the sensitivities of each method, differ-
ences in the manner in which off-targets are identiﬁed (detection
of the DSBs, indels after NHEJ, or translocations), and differences in
the gRNA sequences used in the studies (for a review of recent off-
target detection methods, see O’Geen et al., 2015; Bolukbasi et al.,
2015).
4.1. Methods for enhancing CRISPR-Cas9 speciﬁcity
Tolerance for the overall level of CRISPR-Cas9 off-targeting
activity will differ based on the type of genome editing application.
For example, therapeutic applications will have a much lower toler-
ance for off-target effects compared to other research applications
such as functional genomics screening where multiple reagents can
and should be used to address the issue of false positive results due
to off-targeting. To enhance the speciﬁcity of CRISPR-Cas9, multi-
ple strategies for improving Cas9 speciﬁcity have been developed,
including design of the gRNA, use of high-ﬁdelity Cas9 mutants, and
formats of CRISPR-Cas9 reagents.
The most straightforward approach for improving reagent
speciﬁcity is to computationally predict off-targets and avoid those
sequences when designing a gRNA. Many computationally pre-
dicted off-target sites have been experimentally conﬁrmed, thereby
supporting the validity of the computational approach. How-
ever, not all actual off-target sites have been predicted using this
approach, including some off-targets with multiple mismatches.
Most extant gRNA speciﬁcity evaluation tools are based solely on
mismatch checking (Heigwer et al., 2014; Bae et al., 2014; Xiao
et al., 2014; Xie et al., 2014 Xiao et al., 2014; Xie et al., 2014) while
some actual off-targets can be explained by the presence of gaps
rather than mismatches between the gRNA and the target DNA (Lin
et al., 2014); this ﬁnding highlights the need for analysis tools that
incorporate not only mismatches but also gaps on gRNA and DNA
target sites. Recent advances have been made to incorporate these
features for a more comprehensive off-target analysis, speciﬁcally
in the COSMID tool (Cradick et al., 2014) as well as the Dhar-
macon CRISPR speciﬁcity tool (http://dharmacon.gelifesciences.
com/tools-and-calculators/crispr-speciﬁcity-tool/; Lenger et al., in
preparation).The structure of the gRNA or the Cas9 protein can also be altered
to improve speciﬁcity. Truncation of the gRNA on the 5′ end from
20 nt to 18 or 17 nt has been shown to preserve nearly all on-target
cleavage activity while reducing activity at off-target sites (Fu
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t al., 2014; Wyvekens et al., 2015). Using two extra G nucleotides
t the 5′ end of the gRNA (GGX20) has also been reported to
mprove the Cas9 nuclease precision (Kim et al., 2015; Cho et al.,
014). Studies on larger sequence sets are necessary to determine
he universality and practical beneﬁts of these alterations, and to
dentify additional sequence positions or structural changes for
ncreased speciﬁcity. Multiple approaches that involve mutations
f the Cas9 protein itself have been described with substantial
mprovement to the Cas9 nuclease speciﬁcity. A Cas9 mutant (Cas9
10A) that transforms the enzyme from a endonuclease that cuts
oth strands to a single-strand nickase has been successfully used
ith paired sgRNAs to introduce nicks in close proximity to both
trands (Mali et al., 2013; Cho et al., 2014; Ran et al., 2013; Shen
t al., 2014 Ran et al., 2013; Shen et al., 2014). While this has been
hown to reduce off-targeting, the need for appropriately posi-
ioned and oriented paired gRNAs can be technically challenging,
specially for genome-scale library-based applications. Recently,
wo groups reported Cas9 variants with increased speciﬁcity by
odifying amino acids in the Cas9 protein that are presumably
nvolved in DNA stabilization: SpCas9-HF1 (a high-ﬁdelity variant
Kleinstiver et al., 2016)) and eSpCas9 (enhanced speciﬁcity Cas9
ariant (Slaymaker et al., 2016)). Both groups showed increased
peciﬁcity as demonstrated by whole genome mutation methods.
his approach of mutating non-speciﬁc DNA contacts could be addi-
ionally extended to other CRISPR nucleases.
Off-targeting can also be ameliorated by controlling the expres-
ion level or persistence of the gRNA and/or Cas9 nuclease. Whole
enome off-target analyses to date have been performed using
xpressed Cas9 and expressed sgRNAs (Tsai et al., 2015; Crosetto
t al., 2013; Wang et al., 2015; Kim et al., 2015; Frock et al., 2015).
owever, continuous expression of Cas9 and sgRNA in cells can lead
o accumulation of off-targeting. Indeed, constitutive expression of
entiviral-based Cas9 and sgRNAs for pooled screening purposes
ead to an enrichment of sgRNA constructs targeting predicted off-
arget sites over time (Wang et al., 2014; Shalem et al., 2014), while
educing the concentration of delivered plasmid during transfec-
ion was shown to decrease off-targeting (Hsu et al., 2013; Wang
t al., 2015). These data support the idea that controlling the expres-
ion of Cas9 and the gRNAs in order to limit the time of action can
urther reduce genome-wide off-targeting.
Synthetic gRNAs can be utilized in CRISPR-Cas9 experiments to
rovide a unique solution for avoidance of long-term expression
hat would lead to off-target effects. Our analysis of mismatch toler-
nce upon delivery of synthetic crRNA:tracrRNA in Cas9-expressing
ells showed that less than 4% of gRNA sequences containing two
ase mismatches to the target DNA remain active (Anderson et al.,
015); this is a lower rate than observed in prior studies using
xpressed sgRNAs in which they found a hit rate of 6–26% of
ismatched off-target sites (Fu et al., 2013; Hsu et al., 2013). Addi-
ionally, studies using gRNAs with recombinant Cas9 nuclease as
 ribonucleoprotein (RNP) complex delivered into cells by electro-
oration have demonstrated substantial decreases in off-targeting
hile maintaining high on-target efﬁciency (Hendel et al., 2015;
im et al., 2014; Ramakrishna et al., 2014; Liang et al., 2015). The
RNA:Cas9 RNPs were shown to cleave the target chromosomal
NA between 12 and 24 h after delivery and the frequency of gene
diting reached a plateau after one day; for plasmid expression
f Cas9 and the gRNA, equivalent gene editing levels were only
chieved at three days after delivery (Kim et al., 2014). Further-
ore, the Cas9 protein has been shown to be degraded rapidly
n cells, within 24–48 h after delivery, compared to several days
hen continuously expressed from a plasmid (Kim et al., 2014;
iang et al., 2015). Kim et al. showed efﬁcient RNP delivery in
uman ﬁbroblasts and pluripotent cells and a reduction in off-
arget mutations obtained with plasmid transfection at off-target
ites that differed by one or two nucleotides from on-target siteshnology 233 (2016) 74–83 79
(Kim et al., 2014). The ratio of the indel frequency at the on-target
site to the off-target sites for two  gRNA decreased from 114 and
279 for plasmid-expressed Cas9, to 12 and 22 for Cas9 RNP deliv-
ery, indicating more than ten-fold higher speciﬁcity. These results
are in agreement with those observed using direct delivery of ZFNs,
which reduces off-target effects associated with plasmid delivery
(Gaj et al., 2012). Using in vitro transcribed gRNA and/or in vitro
transcribed Cas9 mRNA will also limit the expression and persis-
tence of CRISPR-Cas9 reagents for lower off-target effects.
Taken together, gRNAs should be designed to avoid known and
predicted off-target sites, and may  also be designed with variations
in the length or sequence composition of the gRNA. Well-designed
gRNAs can be used in conjunction with mutated Cas9 nucleases
to avoid off-targeting. Importantly, a DNA-free approach, such as
using synthetic crRNA:tracrRNA and Cas9 protein or Cas9 mRNA,
can further control the expression level and duration of activity of
both the gRNA and Cas9 for increased speciﬁcity.
5. Gene editing applications using synthetic guide RNAs
With the variety of reagent formats available for gRNAs (chemi-
cally synthesized, expressed, in vitro transcribed) and Cas9 (protein,
mRNA, expressed), the CRISPR-Cas9 system can be suited for many
distinct genome engineering applications. Vector-based CRISPR-
Cas9 systems require cloning and sequence veriﬁcation of each
sgRNA vector which can be laborious, especially if the goal is
studying tens or thousands of gene targets. Likewise, in vitro tran-
scribed sgRNAs also require additional time and quality control to
ensure consistency in length and purity of the transcribed gRNA.
In contrast, chemical synthesis can easily be employed for rapid
generation of the crRNA and tracrRNA molecules or the synthetic
sgRNA for direct delivery into cells. This approach enables appli-
cations unique to synthetic gRNAs including arrayed screening for
gene knockout studies with a variety of phenotypic readouts and
at whole-genome scale as well as DNA-free methods for clonal cell
line development.
5.1. Genome-scale screening applications
Shortly after the discovery of the CRISPR-Cas9 system for gene
editing in mammalian cells, vector-based sgRNA pools were gen-
erated and used to perform genome-scale loss-of-function screens
in a pooled format (Wang et al., 2014; Shalem et al., 2014). Despite
their power as a functional genomics tool, pooled sgRNA screens
are limited by the types of assays that are amenable to read-
outs in a population of cells; speciﬁcally, the phenotypes must be
selectable or sortable in order to distinguish hits from non-hits
in the cell population. The ability to perform CRISPR-Cas9 loss-
of-function screens in an arrayed, well-by-well fashion expands
the types of phenotypic readouts that can be used. For exam-
ple, arrayed screens can be performed using high-content and
morphology-based assays, and can include the measurement of
multiple parameters either in an end-point or a kinetic fashion,
using time lapse images. Vector-based arrayed screening reagents
are available but have associated challenges with the number of
steps necessary to prepare the delivery reagents for screening,
which can impact data quality and lead to biased results; these
challenges include variability in expression levels of the sgRNA
and/or Cas9 nuclease and well-to-well variability in transfection
of plasmid components or the titer of packaged lentiviral particles.
Chemical synthesis of gRNAs for CRISPR-Cas9 gene editing, on the
other hand, allows for accurate and rapid production of arrayed
gRNA libraries with high well-to-well consistencies from reagent
purity and normalized concentrations.
80 M.L. Kelley et al. / Journal of Biotechnology 233 (2016) 74–83
Fig. 5. High throughput arrayed screening applications with phenotypic assays using dual RNAs. (a) A general workﬂow for screening with arrayed synthetic
crRNA:tracrRNA, starting with generation of stable cells expressing Cas9 nuclease and ending with the phenotypic readout. U2OS-Ubi[G76V]-EGFP cells that stably
express Cas9 under a CAG promoter were generated and examined for editing efﬁciency using control crRNA (see Fig. 2B). These U2OS-Ubi[G76V]-EGFP-CAG-Cas9 cells
were  then used in several downstream phenotypic assays (b-d). (b) Proteasome function assays: cells were seeded at 4300 cells/well in black 96-well tissue culture
plates and were transfected the following day with synthetic crRNA:tracrRNA (50 nM)  targeting PPIB, PSMD7 or VCP genes using DharmaFECT 4 transfection reagent
(0.07  g/well). After 72 h the EGFP ﬂuorescence was imaged and measured using an Envision plate reader (Perkin Elmer). (c) Apoptosis assay: cells seeded at 10,000
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completely DNA-free solution. Synthetic RNAs in combination with
non-viral delivery methods such as electroporation may  be among
the ﬁrst strategies used for ex vivo editing in a cell therapy setting.
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As a ﬁrst step for a generalized arrayed screening workﬂow
sing synthetic crRNA:tracrRNA, we recommend generating Cas9-
xpressing stable cell lines if possible. Generation of Cas9 stable
ell lines enables higher phenotypic penetrance and simpliﬁes the
elivery of the synthetic gRNAs for arrayed screening (Fig. 5a). We
ave shown that knockout of proteasome-related genes by high-
hroughput transfection of synthetic crRNA:tracrRNA in a U2OS
bi[G76V]-EGFP reporter cell line lead to an increase of EGFP signal,
emonstrating that arrayed synthetic gRNAs can be used to perform
unctional gene knockout screens (Anderson et al., 2015). While the
henotype could be observed when synthetic crRNA:tracrRNA are
o-delivered with Cas9 expression plasmid (data not shown), we
nd that the efﬁciency of editing and the phenotypic response was
igher and more consistent when the synthetic gRNAs are delivered
nto U2OS Ubi[G76V]-EGFP cells that stably express Cas9 (Fig. 5b).
We have since performed several additional phenotypic
eadouts using Cas9-expressing cells, including a homogenous
aspase-3/7 enzymatic assay. Transfection of Cas9-expressing
2OS cells with synthetic crRNA:tracrRNAs targeting 16 genes
dentiﬁed three genes (PLK1, KIF11 and BCL2L1) that lead to
ncreased apoptosis, as measured by the Apo-ONE® Caspase-3/7
omogeneous assay (Promega) at 72 h post-transfection (Fig. 5c).
n addition, transfection with synthetic crRNA:tracrRNAs target-
ng PLK1 and KIF11 genes that play a role in mitosis resulted in a
ecrease in overall cell number and a 5- to 7-fold increase in mitotic
ndex at 48 h post-transfection as measured by the percent of cells
tained for phospho-histone H3 using a high content analysis sys-
em (Fig. 5d). These assays demonstrate that efﬁcient phenotypic
enetrance is elicited by the CRISPR-Cas9 system upon delivery of
ynthetic crRNA:tracrRNA molecules. The assays we used were all
erformed in a cell population using a short-term assay without
he need for enrichment using cell sorting or antibiotic selection.
iven the ease of transfecting RNAs into most cell types, as well
s the ability to create and use Cas9-expressing stable cell lines,
any phenotypic assays are expected to be amenable to arrayed
creening using synthetic crRNA:tracrRNA.
For cell types where generation of Cas9-stable lines is not fea-
ible (e.g., primary cells), the synthetic crRNA:tracrRNAs could be
fﬁciently co-delivered with Cas9 mRNA or Cas9 protein, although
his would certainly add to the transfection optimization and cost
f the screening. Similarly, for cells resistant to lipid-based trans-
ection reagents, electroporation of synthetic gRNAs with Cas9
RNA or Cas9 protein could be used. With the recent availabil-
ty of arrayed collections of predesigned synthetic crRNAs for
igh-throughput gene editing studies across gene families (Dhar-
acon, part of GE Healthcare), we anticipate a signiﬁcant number
f arrayed knockout screens using synthetic gRNAs to be published
n the near future (Agrotis and Ketteler, 2015).
.2. DNA-free genome engineering applications
Because gene editing results in a permanent change in the
enome, once the gene editing event has occurred, it is no longer
ecessary for the CRISPR-Cas9 reagents to be expressed or persist
n the cell. As discussed above, there may  be disadvantages to hav-
ng active gene editing reagents remain in cells, such as an increase
n generation of non-speciﬁc DSBs in the genome (Fu et al., 2013;
attanayak et al., 2013; Lin et al., 2014; Cradick et al., 2013; Tsai
t al., 2015; Fu et al., 2014; Cho et al., 2014; Hsu et al., 2014 Hsu et al.,
ells/well in 96-well format were transfected the following day with ﬁve different crRNA
ontrol (red) and non-targeting siRNA (NTC; green) and crRNA:tracrRNA targeting PPIB
aspase-3/7 homogeneous assay (ApoONE, Promega) at 48 h post-transfection. Data wer
n  96-well format were transfected the following day with crRNA:tracrRNA (25 nM)  targe
ost-transfection and stained with anti-PH3 antibody and Hoechst 33342 before analysis
f  the references to colour in this ﬁgure legend, the reader is referred to the web version hnology 233 (2016) 74–83 81
2014). While off-target effects may  be less of a concern in screening
applications since any identiﬁed “hits” will be conﬁrmed through
follow up experiments, constitutive expression or high stability of
the Cas9 nuclease and/or the gRNA may  be undesirable for many
applications, such as generation of clonal cell lines for perpetual
studies of knockout of a speciﬁc gene.
In addition to the increased potential for off-target effects due to
constitutive expression of components of the CRISPR-Cas9 system,
we (unpublished), and others, have found incorporation of portions
of plasmid sequence used to deliver and express the CRISPR-Cas9
components during the NHEJ repair process of the Cas9-induced
DSB (Hendel et al., 2014). Using a DNA-free CRISPR-Cas9 approach
avoids unwanted incorporation of the plasmid DNA into the cell’s
genome. DNA-free gene editing workﬂows can be uniquely and eas-
ily attained with synthetic gRNAs. Because unmodiﬁed RNAs are
rapidly degraded in cells, gRNAs only need to be sufﬁciently sta-
ble to interact with Cas9, bind the target DNA, and allow cutting
by Cas9 nuclease. In order to achieve rapid gene editing with syn-
thetic gRNAs, the Cas9 nuclease needs to be readily available for
interaction with the gRNA; this can be achieved when Cas9 is co-
delivered as mRNA or protein and does not require transcription
and/or translation, respectively.
Another advantage of the DNA-free system is to remove the
variability that can arise from the choice of promoter used to
drive expression from vector-based CRISPR-Cas9 systems. It is well
known that not all promoters are functional in every cell type or cell
line, so delivery of Cas9 protein or Cas9 mRNA avoids incompatibil-
ities of certain promoters in speciﬁc cells. Overall, the functionality
of the Cas9 and gRNA RNP complexes has been anecdotally reported
as being superior to other methods of delivery, although a compre-
hensive comparison has not yet been performed.
6. Concluding remarks and future perspectives
The use of synthetic gRNAs for CRISPR-Cas9 genome engineer-
ing has a number of advantages over vector-based components,
including removing the time and labor for cloning sgRNA expres-
sion cassettes or generation and puriﬁcation of in vitro transcribed
sgRNAs, removing the potential for additional off-target effects by
prolonged sgRNA expression or avoiding unwanted genetic scar-
ring through incorporation of vector sequence into the genome.
Using synthetic oligonucleotide CRISPR-Cas9 components that can
be added exogenously will enable better delivery and formu-
lation strategies in cell culture as well as in other organisms
(Guzman-Villanueva et al., 2012). Chemically modiﬁed, conjugated,
and/or nanoparticle formulated-gRNAs will enhance the stability
of gRNAs that is required for some applications, increase gene
editing potency, and potentially further reduce off-target effects.
Additionally, the synthetic approach enables arrayed gene knock-
out screening in a high-throughput manner as well as offering aFuture versions of gRNA constructs with deﬁned size, modiﬁcation,
structure, and functionality will continue to improve the efﬁcacy
and speciﬁcity of the CRISPR-Cas9 system.
:tracrRNA (25 nM)  targeting 16 different genes. PLK1 siRNA was used as a positive
 were used as negative controls. The effects on apoptosis were assayed using a
e normalized to negative control. (d) Mitotic Index: cells seeded at 5000 cells/well
ting PLK1 and KIF11 or non-targeting crRNA controls (NTC). Cells were ﬁxed at 48 h
 on the IN Cell Analyzer 2200 imaging system (GE Healthcare). (For interpretation
of this article.)
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